🇺🇸

US SEC Filing Intelligence

· daily

Significant Contract Modifications ($10M+) — June 28, 2026

The three contracts total $2.51 billion, with a 2:1 civilian-to-defense split by value. The dominant theme is civilian biodefense and health administration, led by a $1.31B DHS award to SLS Federal Services LLC and an $857.6M HHS/ASPR contract to Emergent Biosolutions for the ACAM2000 smallpox vaccine. The highest-conviction signal is the Emergent contract, which provides long-term revenue visibility through 2029, though execution risk is elevated due to its firm fixed-price structure. A key risk is the negative outlay (-$762K) on the CGS Administrators CMS contract, which may indicate program delays or termination risk. No defense-specific contracts were identified beyond the DHS award, limiting defense sector exposure in this digest.

3 total filings
· daily

Contract Deobligations Alert — June 28, 2026

This digest covers $2.51 billion in total obligations across three contracts, with a heavy civilian tilt (two HHS awards totaling $1.20 billion) and one DHS defense-related award of $1.31 billion. The highest-conviction signal is Emergent Biosolutions' $857.6 million firm fixed-price contract for the ACAM2000 smallpox vaccine, offering long-term revenue visibility through 2029 but with execution risk due to fixed-price cost burden. The DHS award to SLS Federal Services LLC is a large, opaque sole-source-like signal with limited public data, warranting caution. A key risk is the negative outlay on CGS Administrators' CMS contract, which may indicate program underperformance or termination. Investors should watch for option exercises on Emergent's contract and any follow-on awards from CMS for health insurance administration.

3 total filings
· daily

Contract Option Exercises — June 28, 2026

The three contract option exercises analyzed, totaling $2.51 billion, are overwhelmingly civilian-focused with a notable biodefense theme, as the Department of Health and Human Services accounts for $1.2 billion (48%) of the aggregate. The highest-conviction signal is Emergent Biosolutions' $857.6 million firm fixed-price ACAM2000 smallpox vaccine contract, which provides decade-long revenue visibility ($85.8M annualized) but carries execution risk due to the fixed-price structure. A critical risk is the $339.5 million CMS contract with CGS Administrators exhibiting a negative outlay (-$762k), potentially signaling program delays or termination risk. The sole defense contract, a $1.31 billion DHS award to SLS Federal Services, lacks pricing details and competitive moat data, limiting its actionable investment value despite its large size.

3 total filings
· daily

All HHS Contracts — June 28, 2026

The two HHS contracts reviewed total $1.197 billion in obligations, with a clear civilian agency focus (no direct defense contracts), though one award is categorized as defense-related due to its biodefense product. The dominant theme is pandemic preparedness and strategic health insurance administration, with Emergent Biosolutions’ $857.6 million ACAM2000 smallpox vaccine contract serving as the highest-conviction signal, offering long-term revenue visibility into 2029. However, the sizable $457.9 million outlayed balance signals strong government commitment, while execution risk from the firm fixed-price structure is notable. CGS Administrators’ $339.5 million CMS contract is neutral and private, offering no direct public equity exposure. Key watch items include Emergent’s outlay pace and contract re-compete dates, as well as CMS budget stability for follow-on awards.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — June 28, 2026

The three contracts totaling $2.51 billion present a bifurcated investment story: a dominant $1.31 billion DHS award to SLS Federal Services LLC (defense-related, bullish) and two civilian HHS contracts—a $857.6 million Emergent Biosolutions smallpox vaccine deal (bullish, high materiality) and a $339.5 million CMS contract to private CGS Administrators (neutral, low materiality). The highest-conviction signal is Emergent Biosolutions' long-term revenue visibility from a firm fixed-price biodefense contract, but execution risk is medium due to pricing structure. Key risk: the CGS contract shows negative outlays (-$762K), suggesting potential underperformance or termination risk. The defense/civilian split is 1:2 by count but 52%/48% by value, with civilian biodefense and healthcare administration dominating.

3 total filings
· daily

High-Value Federal Grants ($5M+) — June 28, 2026

This digest covers three high-value federal grants totaling $2.51 billion, with a pronounced civilian agency focus—two contracts from HHS ($1.20B combined) and one from DHS ($1.31B). The dominant theme is biodefense and health security, led by Emergent Biosolutions' $857.6M firm fixed-price ACAM2000 smallpox vaccine contract, which offers long-term revenue visibility but carries execution risk due to fixed-price pricing. The highest-conviction signal is the $1.31B DHS award to SLS Federal Services, though data gaps on pricing and competition limit confidence. A key risk is the negative outlay on CGS Administrators' $339.5M CMS contract, signaling potential underperformance or termination. Overall, the digest suggests stable civilian spending on health and homeland security, but investors should watch for program delays and re-compete dynamics.

3 total filings
· daily

General Federal Contracts — June 28, 2026

This digest covers $2.51B in total obligations across three contracts, with a 1/3 defense-related split (one DHS award) and two civilian HHS awards. The dominant theme is biodefense and health security, driven by Emergent BioSolutions' $857.6M firm fixed-price ACAM2000 smallpox vaccine contract from HHS/ASPR, which provides long-term revenue visibility through 2029 but carries execution risk under fixed-price terms. The highest-conviction signal is the $1.31B sole-source-like DHS award to SLS Federal Services, though limited data prevents full assessment. A key risk is the negative outlay on CGS Administrators' $339.5M CMS contract, which may signal underperformance or termination risk, limiting direct public equity exposure.

3 total filings
· daily

VA Healthcare & Services Contracts — June 27, 2026

Two large, short-duration firm-fixed-price delivery orders totaling $1.78 billion were awarded exclusively to TriWest Healthcare Alliance Corp. by the Department of Veterans Affairs for health insurance carrier services, representing a 100% civilian (non-defense) concentration. The aggregate obligation is massive, but both contracts have performance periods of only one month (April and May 2026) with zero outlayed funds to date, signaling possible bridge or urgent-need arrangements rather than recurring revenue. The highest-conviction signal is neutral: the awards demonstrate TriWest’s competitive win capability under full-and-open competition, but the extreme short duration and lack of options create material execution risk and limited forward visibility. Key risk is that these may be one-time emergency awards tied to budget constraints, with no guarantee of follow-on contracts, making the implied annualized revenue (~$10.8B) highly speculative.

2 total filings
· daily

New Federal Contractors — June 27, 2026

The two contracts awarded to TriWest Healthcare Alliance Corp. by the Department of Veterans Affairs on June 25, 2026, total $1.78 billion in obligations, both for direct health and medical insurance carrier services. Both are civilian (non-defense) awards, representing a dominant theme of VA health insurance spending, but the extremely short performance periods (one month each for April and May 2026) signal potential bridge or urgent needs rather than sustained recurring revenue. The highest-conviction signal is neutral, given the large dollar amounts but limited duration and zero outlayed funds to date, which introduces execution and budget risk. Key watch items include whether TriWest secures follow-on contracts or extensions beyond these one-month terms and whether VA budget allocations for health insurance programs remain robust.

2 total filings
· daily

Significant Contract Modifications ($10M+) — June 27, 2026

Over a single day, the Department of Veterans Affairs awarded two large firm-fixed-price delivery orders totaling $1.78 billion to TriWest Healthcare Alliance Corp. for direct health and medical insurance services. Both contracts are civilian, not defense-related, and each has an extremely short one-month performance period (April and May 2026), with zero outlayed funds to date. The highest-conviction signal is neutral: the awards suggest robust VA spending on health insurance programs, but the short durations and lack of options indicate these may be urgent or bridging arrangements rather than recurring revenue streams. A key risk is execution and budget uncertainty, as the compressed timelines and zero outlays raise questions about contract performance and follow-on sustainability.

2 total filings
· daily

Contract Deobligations Alert — June 27, 2026

Two massive, back-to-back firm-fixed-price delivery orders totaling $1.78 billion were awarded to TriWest Healthcare Alliance Corp. by the Department of Veterans Affairs in June 2026, covering one-month performance periods in April and May 2026. Both contracts are civilian (non-defense) and carry neutral signals, reflecting substantial near-term revenue concentration but significant execution and sustainability risks due to their extremely short durations and zero outlayed funds. The dominant theme is urgent or bridge health insurance administration spending by the VA, with no competitive moat evidence and no follow-on visibility. Key risks include the lack of recurring revenue visibility and potential budget constraints driving these short-term arrangements.

2 total filings
· daily

Contract Option Exercises — June 27, 2026

Two contracts totaling $1.78 billion were awarded to TriWest Healthcare Alliance Corp. by the Department of Veterans Affairs on June 25, 2026, both for direct health and medical insurance carrier services. Both are firm-fixed-price delivery orders with extremely short one-month performance periods (April and May 2026), suggesting urgent or bridge requirements rather than recurring revenue streams. No defense-related contracts were included, and both signals are neutral with an average strength of 5.5/10. The key risk is the lack of outlayed funds and short duration, which limits long-term revenue visibility and raises questions about sustainability of VA health insurance spending at this pace. Investors should monitor for follow-on contracts or extensions to assess whether this is a one-time surge or a new baseline for TriWest's VA business.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — June 27, 2026

The two contracts analyzed, both awarded to TriWest Healthcare Alliance Corp. by the Department of Veterans Affairs, total $1.78 billion in obligations but cover only two separate one-month performance periods (April and May 2026). These are civilian agency awards with no defense-related content, and the short durations—combined with zero outlayed funds on one contract—suggest urgent, bridge, or stopgap arrangements rather than sustained, recurring revenue streams. The highest-conviction signal is the sheer size of the monthly obligations (over $900M each), which could materially impact TriWest's near-term cash flows if executed, but the lack of options and limited visibility into follow-on awards create significant execution and budget risk. Key risks include the possibility that these are one-time bridge contracts tied to VA budget constraints or program transitions, and the absence of outlayed funds on the April contract raises questions about actual performance and payment timing.

2 total filings
· daily

High-Value Federal Grants ($5M+) — June 27, 2026

Over a single day, TriWest Healthcare Alliance Corp. secured two massive firm-fixed-price delivery orders from the Department of Veterans Affairs totaling $1.78 billion, representing the entire stream's obligation. Both contracts are civilian (non-defense) and carry neutral signals, as the extremely short one-month performance periods (April and May 2026) and zero outlayed funds suggest these are urgent or bridging arrangements rather than sustainable recurring revenue. The dominant theme is a surge in VA health insurance spending, but the lack of options and short duration introduce execution and budget risk. The highest-conviction signal is the concentration risk to TriWest, which now faces a $1.78 billion revenue cliff if no follow-on awards materialize. Key watch items include outlayed fund tracking and any VA announcements regarding program continuity.

2 total filings
· daily

General Federal Contracts — June 27, 2026

Two contracts totaling $1.78 billion were awarded to TriWest Healthcare Alliance Corp. by the Department of Veterans Affairs on June 25, 2026, both for direct health and medical insurance carrier services. Both are firm-fixed-price delivery orders with extremely short one-month performance periods (April and May 2026), and neither is defense-related, reflecting a pure civilian healthcare administration theme. The highest-conviction signal is neutral: the awards are large in absolute terms but appear to be bridge or urgent-need contracts rather than recurring revenue streams, with zero outlayed funds to date on the $873.9 million award. Key risk is the lack of long-term visibility and potential budget constraints driving short-duration awards, which could signal instability in VA health insurance program funding.

2 total filings
· daily

Biotech Small-Cap Approvals — June 26, 2026

The June 26, 2026, biotech small-cap approval stream delivered six generic drug approvals (classified as 'Other'), with zero NMEs, biosimilars, or label expansions. All six approvals are neutral signals, reflecting low commercial materiality and no therapeutic area clustering. The most notable sponsor is MACLEODS PHARMS LTD, which received two approvals (RIFAPENTINE and BUPROPION HYDROCHLORIDE), indicating a modest pipeline execution capability in generics. TEVA PHARMS INC's approval of ETHINYL ESTRADIOL underscores its continued generic portfolio expansion. The absence of NMEs or breakthrough therapies limits differentiated investment insights; the key risk is the lack of high-value catalysts in this period.

6 total filings
· daily

Big Pharma Approvals — June 26, 2026

This period delivered 4 label expansion approvals, all classified as 'Other' with no NMEs or biosimilars, indicating a maintenance-oriented approval cycle. The dominant therapeutic area is oncology, with Merck's KEYTRUDA (pembrolizumab) and Pfizer's IBRANCE (palbociclib) each receiving two approvals on the same date—signal both sponsors are extending their leading franchises into additional indications. The highest-conviction signal is the dual expansion for KEYTRUDA, reinforcing Merck's position as the undisputed immuno-oncology leader and extending its peak revenue runway beyond the LOE cliff. A key watch item is that both drugs are blockbusters facing eventual IRA Medicare negotiation (small molecule IBRANCE at year 9, biologic KEYTRUDA at year 13), so each label expansion directly adds 'negotiation-proof' revenue years.

4 total filings
· daily

Orphan Drug Approvals — June 26, 2026

The June 26, 2026 orphan drug approval period featured zero NMEs, zero biosimilars, and zero label expansions, with both approvals classified as 'Other' (likely administrative or device-related label updates). The dominant therapeutic area theme is absent, as OLEZARSEN SODIUM (IONIS PHARMS INC) and PEMBROLIZUMAB (MERCK SHARP DOHME) target distinct indications. The highest-conviction signal is the label expansion for KEYTRUDA (pembrolizumab), reinforcing Merck's dominant oncology franchise, though the lack of disclosure on indication size or sales estimates limits conviction. Key risk: both approvals are low-materiality events with no disclosed commercial data, offering limited actionable intelligence for investors.

2 total filings
· daily

New Drug Approvals (Original) — June 26, 2026

The June 26, 2026 FDA approval stream is entirely composed of six FALLBACK-type biosimilar/AB-rated generic approvals, with zero NMEs, zero novel label expansions, and zero biosimilars under the traditional 351(k) pathway. The period lacks any FDA Breakthrough, Priority Review, Orphan Drug, or Accelerated Approval designations, resulting in six neutral signals and no immediate bullish or bearish catalysts for the traded universe. The dominant theme is generic drug entry into established small-molecule markets, with Macleods Pharma Ltd securing approvals for RIFAPENTINE and BUPROPION HYDROCHLORIDE, while Micro Labs, Rubicon Research, Actavis Elizabeth, and Teva Pharmaceuticals each received one approval. No significant therapeutic area clustering or sponsor pipeline strength signal is evident. The key watch item is the complete absence of NMEs, suggesting a low-catalyst day for large-cap pharma and growth-stage biotech investors, with the most relevant exposure being Teva's continued generic manufacturing capability via ETHINYL ESTRADIOL approval.

6 total filings
· daily

Federal Construction & Infrastructure Contracts — June 26, 2026

A single $341.5 million GSA contract to Gilbane-Grunley JV for the Herbert C. Hoover Building modernization formed the entirety of this period's federal construction digest, but it is entirely historical—the contract ended in September 2022 with only $862,554 in outlays remaining. The civilian-only, non-defense nature of this award underscores a lack of current procurement activity, and the neutral signal strength (3/10) combined with zero active revenue visibility offers no actionable forward trigger for investors. A key watch item is that no new GSA construction task orders or re-competes for Hoover Building phases were detected, limiting near-term growth signals for federal construction contractors.

1 total filings